Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference

Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023 at 12 p.m. EST.

The presentation will be available virtually and participants can register here: here. The presentation will be available following the conference on Quanterix’s website here: ir.quanterix.com.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Media:

PAN Communications

Maya Nimnicht

510-334-6273

[email protected]

Investor Relations:

Ed Joyce

(610) 306-9917

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Technology Research Neurology Genetics Other Technology Health General Health Science Oncology

MEDIA:

Logo
Logo

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical’s website at investors.talisbio.com. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.

The webcast will be archived and will be available for replay via the News & Events page following the call.

About Talis Biomedical

Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.

Contact

Media & Investors
Emily Faucette
[email protected]
415-595-9407



New Virtual I-9 Document Review Service Coming Soon from Sterling and ID.me

Employers Will Have a Secure, Modernized Solution for Remote I-9 Document Review

INDEPENDENCE, Ohio and MCLEAN, Va., Aug. 03, 2023 (GLOBE NEWSWIRE) — Sterling Check Corp. (NASDAQ: STER) (“Sterling”), the largest provider of identity and background services, and ID.me, the market leading digital identity and credentials network, today announced they will be launching a new virtual I-9 document review service in the coming weeks. As part of the existing Sterling I-9 solution, ID.me Trusted Referees will examine documents virtually, securely, and conveniently, enabling employers to complete I-9 requirements remotely for their new hires.

ID.me and Sterling’s new solution is built upon the recently announced alternative verification procedures from Department of Homeland Security (DHS) and United States Citizenship and Immigration Services (USCIS). Instead of relying on in-person review conducted by an employer or 3rd party notary, ID.me’s expert Trusted Referees will be available to complete secure virtual document review on behalf of the employer.

The ID.me Trusted Referees are screened and trained to Department of Commerce standards for identity proofing set by the National Institute of Standards and Technology (NIST). Currently 14 federal agencies and 35 state government agencies rely on ID.me’s Trusted Referees to verify users.

The virtual document review process will be available to new and existing Sterling I-9 clients who are also E-Verify users in good standing. The entire process can be completed remotely in 5-10 minutes and is compliant with DHS and USCIS requirements. All documents examined by ID.me Trusted Referees are retained along with all other I-9 documents in the Sterling system and available to employers for audit purposes.

“Our clients have been requesting a more modern, secure I-9 document verification solution for years,” said Josh Peirez, CEO of Sterling. “Sterling’s new virtual review service will streamline the I-9 document verification experience for the virtual work environment.”

This solution builds upon Sterling’s innovative suite of identity verification solutions for US employers, offered through an exclusive partnership with ID.me.

“We applaud the Department of Homeland Security for modernizing onboarding processes to allow for a secure, remote option for I-9 document review,” said Blake Hall, CEO of ID.me. “Our Trusted Referees are expertly trained to examine identity documents, and this service can help thousands of employers to efficiently comply with DHS requirements by leveraging video chat to complete Form I-9.”

This new solution will be available exclusively to Sterling I-9 clients in the coming weeks. Visit https://www.sterlingcheck.com/services/form-i-9-e-verify/ to learn more.

About Sterling

Sterling (NASDAQ: STER) — a leading provider of background and identity services — offers background and identity verification to help over 50,000 clients create people-first cultures built on a foundation of trust and safety. Sterling’s tech-enabled services help organizations across all industries establish great environments for their workers, partners, and customers. With operations around the world, Sterling conducted more than 110 million searches in the twelve months ending December 31, 2022. Visit us at www.sterlingcheck.com.

About ID.me

ID.me simplifies how individuals prove and share their identity online. More than 110 million members can use their ID.me Wallet to easily verify their identity across 31 states, 14 federal agencies, and over 500 name-brand retailers across ID.me’s secure digital identity network. The company provides secure login, identity proofing, and community affiliation verification for organizations across sectors. ID.me’s technology meets the federal standards for consumer authentication set by the Commerce Department and is approved as a NIST 800-63-3 IAL2 / AAL2 credential service provider by the Kantara Initiative. ID.me is committed to “No Identity Left Behind” to enable all people to have a secure digital identity. To learn more, visit www.ID.me.

Contacts

Sterling: Jodi Perkins | [email protected]
ID.me: Kevin Madden | [email protected]



Brightcove to Present at the Oppenheimer Technology, Internet & Communications Conference

Brightcove to Present at the Oppenheimer Technology, Internet & Communications Conference

BOSTON–(BUSINESS WIRE)–Brightcove Inc. (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced that its Chief Executive Officer, Marc DeBevoise, and Chief Financial Officer, Rob Noreck, will present at the Oppenheimer Technology, Internet & Communications Virtual Conference.

The Brightcove presentation is scheduled for Wednesday, August 9, 2023 at 4:35 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Brightcove investor relations website at https://investor.brightcove.com/events-presentations. A replay of the webcast will also be available for a limited time.

About Brightcove

Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on Twitter, LinkedIn, and Facebook. Visit www.brightcove.com.

Investor Contact:

ICR for Brightcove

Brian Denyeau, 646-277-1251

[email protected]

Media Contact:

Brightcove

Sara Griggs, 929-888-4866

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Software Internet Film & Motion Pictures TV and Radio Online Consumer Electronics Technology Entertainment

MEDIA:

Teledyne to Hold Investor Meetings

Teledyne to Hold Investor Meetings

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–
Teledyne Technologies Incorporated (NYSE:TDY) today announced that Jason VanWees, Vice Chairman, will be holding investor meetings at the 11th Annual Needham Virtual Industrial Tech, Robotics, & Clean Tech 1×1 Conference on Friday, August 4.

Teledyne’s latest investor presentation will be publicly available on the Company’s website at www.teledyne.com/investors/events-and-presentations.

Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne’s operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne’s website at www.teledyne.com.

Cautionary Statement Regarding Forward-Looking Statements

Teledyne’s investor presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, with respect to management’s beliefs about the financial condition, results of operations and businesses of Teledyne in the future. Forward-looking statements involve risks and uncertainties, are based on the current expectations of the management of Teledyne and are subject to uncertainty and changes in circumstances. The forward-looking statements contained herein may include statements relating to stock option compensation expense, and about the continuing expected effects on Teledyne of the acquisition of FLIR and synergies related to the transaction, anticipated capital expenditures and product developments, and other strategic options. Forward-looking statements generally are accompanied by words such as “projects,” “intends,” “expects,” “anticipates,” “targets,” “estimates,” “will” and words of similar import that convey the uncertainty of future events or outcomes. All statements made in this communication that are not historical in nature should be considered forward-looking. By its nature, forward-looking information is not a guarantee of future performance or results and involves risks and uncertainties because it relates to events and depends on circumstances that will occur in the future.

Actual results could differ materially from these forward-looking statements. Many factors could change the anticipated results, including: ongoing challenges and uncertainties posed by the COVID pandemic for businesses and governments around the world, including production, supply, contractual and other disruptions, such as COVID-related lockdowns, facility closures, furloughs and travel restrictions; changes in relevant tax and other laws; foreign currency exchange risks; rising interest rates; risks associated with indebtedness, as well as our ability to reduce indebtedness and the timing thereof; the impact of semiconductor and other supply chain shortages, higher inflation, including wage competition and higher shipping costs; labor shortages and competition for skilled personnel; the inability to develop and market new competitive products; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards; disruptions in the global economy; the ongoing conflict between Russia and Ukraine, including the impact to energy prices and availability, especially in Europe; customer and supplier bankruptcies; changes in demand for products sold to the defense electronics, instrumentation, digital imaging, energy exploration and production, commercial aviation, semiconductor and communications markets; funding, continuation and award of government programs; cuts to defense spending resulting from existing and future deficit reduction measures or changes to U.S. and foreign government spending and budget priorities triggered by the COVID pandemic; impacts from the United Kingdom’s exit from the European Union; uncertainties related to the policies of the U.S. Presidential Administration; the imposition and expansion of, and responses to, trade sanctions and tariffs; the continuing review and resolution of FLIR’s export and tax matters; escalating economic and diplomatic tension between China and the United States; threats to the security of our confidential and proprietary information, including cybersecurity threats; natural and man-made disasters, including those related to or intensified by climate change; and our ability to achieve emission reduction targets and decrease our carbon footprint. Lower oil and natural gas prices, as well as instability in the Middle East or other oil producing regions, and new regulations or restrictions relating to energy production, including those implemented in response to climate change, could further negatively affect our businesses that supply the oil and gas industry. Weakness in the commercial aerospace industry negatively affects the markets of our commercial aviation businesses. In addition, financial market fluctuations affect the value of the Company’s pension assets. Changes in the policies of U.S. and foreign governments, including economic sanctions, could result, over time, in reductions or realignment in defense or other government spending and further changes in programs in which the Company participates.

We continue to take action to assure compliance with the internal controls, disclosure controls and other requirements of the Sarbanes-Oxley Act of 2002. While we believe our control systems are effective, there are inherent limitations in all control systems, and misstatements due to error or fraud may occur and may not be detected. Additional factors that could cause results to differ materially from those described above can be found in Teledyne’s 2022 Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and in other documents which are on file with the SEC and available in the “Investors” section of Teledyne’s website, teledyne.com, under the heading “Investor Information.”

All forward-looking statements speak only as of the date they are made and are based on information available at that time. Teledyne does not assume any obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.

Jason VanWees

(805) 373-4542

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Other Defense Engineering Photography Aerospace Software Manufacturing Hardware Robotics Defense

MEDIA:

Perma-Fix Reports 29% Increase in Revenue to $25 Million for the Second Quarter of 2023

Gross profit increases 57%; achieves net income of $474 thousand

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the second quarter ended June 30, 2023.

Mark Duff, President and CEO of the Company, commented, “We are on a solid growth trajectory and have returned to profitability following the impact of the COVID-19 pandemic. Specifically, revenue increased 28.7% to $25.0 million and we achieved a 56.6% increase in gross profit over the same period last year. Revenue increased year-over-year and sequentially within both our Treatment and Services segments. Importantly, we achieved net income of $474,000 and EBITDA (as defined below) of more than $1.5 million for the second quarter of 2023.”

“Within our Treatment Segment, we witnessed an increase in volume with strong waste receipts during the second quarter, which provides us a solid backlog and improved visibility for the balance of 2023. Within the Services Segment, we realized several new awards, including a project in support of the U.S. Army Corps of Engineers, and were on a winning team for a project at Los Alamos National Laboratory, both of which will contribute revenue in 2023. We also commenced work on awards granted earlier this year, that have now begun to generate revenue. Importantly, we continue to develop new proposals and position ourselves for large strategic bids in both segments, including initiatives within the U.S. Department of Energy (DOE) and the U.S. Department of Defense (DOD), as well as international and commercial clients. Overall, we are encouraged by the market outlook given our strong sales pipeline, with many of these contracts expected to be awarded in the coming quarters.”

Financial Results

Revenue for the second quarter of 2023 was approximately $25.0 million versus approximately $19.5 million for the same period last year. Revenue for the Treatment Segment was approximately $12.8 million for the second quarter of 2023 as compared to $8.4 million for the second quarter 2022. The increase was primarily due to overall higher waste volume which was offset by lower averaged price due to revenue mix. The Treatment Segment has seen steady improvements in waste receipts since the latter part of the second quarter of 2022 as the lingering effects of the COVID-19 continued to subside. Services Segment revenue increased to approximately $12.2 million for the three months ended June 30, 2023 from $11.1 million for the corresponding period of 2022 due to continuing full operational status of certain projects which had been delayed/curtailed in the early part of 2022 due, in part, from the lingering effects of COVID-19. Revenue within both segments was also positively impacted from new contracts won in early part of 2023.

Gross profit for the second quarter of 2023 was $4.5 million versus $2.9 million for the second quarter of 2022 primarily due to higher revenue generated in both segments. Gross margin for the second quarter of 2023 was approximately 18.0% versus 14.8% for the second quarter of 2022 primarily due to increases in revenue from higher waste volume in the Treatment Segment and higher margin projects in the Services Segment.

Operating income for the second quarter of 2023 was approximately $844,000 versus operating loss of $880,000 for the second quarter of 2022. Net income for the second quarter of 2023 was approximately $474,000 or $.04 per basic share as compared to net loss of approximately $1.4 million for the second quarter of 2022 or ($0.11) per basic share.

On July 31, 2023, the Company entered into an amendment to its Loan Agreement, as amended, with its lender which extended the maturity date of its credit facility to May 15, 2027 and provided a new term loan to the Company in the amount of $2,500,000, among other things.

The Company reported EBITDA of $1.5 million from continuing operations for the quarter ended June 30, 2023, as compared to EBITDA of ($403,000) from continuing operations for the same period of 2022. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. EBITDA is not a measure of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA is relevant and useful by enhancing the readers’ ability to understand the Company’s operating performance. The Company’s management utilizes EBITDA as a mean to measure performance. The Company’s measurement of EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA, a non-GAAP measures, to GAAP numbers for income (loss) from continuing operations for the three and six months ended June 30, 2023 and 2022.

    (Unaudited)   (Unaudited)  
    Three Months Ended   Six Months Ended  
    June 30,   June 30,  
(In thousands)     2023       2022       2023       2022    
Income (loss) from continuing operations   $ 519     $ (1,257 )   $ 202     $ (2,506 )  
                   
                   
Adjustments:                  
Depreciation & amortization     692       480       1,439       936    
Interest income     (172 )     (29 )     (298 )     (40 )  
Interest expense     47       41       100       76    
Interest expense – financing fees     24       15       44       28    
Income tax expense (benefit)     432       347       228       (326 )  
                   
EBITDA   $ 1,542     $ (403 )   $ 1,715     $ (1,832 )  
                   

The tables below present certain unaudited financial information for the business segments, which excludes allocation of corporate expenses.

    Three Months Ended   Six Months Ended
    June 30, 2023   June 30, 2023
    (Unaudited)     (Unaudited)
(In thousands)   Treatment   Services     Treatment   Services  
Net revenues   $ 12,834   $ 12,198     $ 22,428   $ 22,711  
Gross profit     2,491     2,025       3,743     3,782  
Segment profit     1,273     840       1,605     1,813  
                     

    Three Months Ended   Six Months Ended
    June 30, 2022   June 30, 2022
    (Unaudited)     (Unaudited)
(In thousands)   Treatment   Services     Treatment   Services  
Net revenues   $ 8,393   $ 11,062     $ 15,872   $ 19,498  
Gross profit     1,563     1,321       2,201     2,319  
Segment profit     60     472       137     871  
                     

Conference Call

Perma-Fix will host a conference call at 11:00 a.m. ET on Thursday, August 3, 2023. The call will be available on the Company’s website at https://ir.perma-fix.com/conference-calls, or by calling toll-free: 888-506-0062 for U.S. callers, or +1 973-528-0011 for international callers, and by entering access code: 789286. The conference call will be led by Mark J. Duff, Chief Executive Officer, Dr. Louis F. Centofanti, Executive Vice President of Strategic Initiatives, and Ben Naccarato, Executive Vice President and Chief Financial Officer of Perma-Fix Environmental Services, Inc.

A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, Thursday, August 10, 2023, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code: 48811.

About Perma-Fix Environmental Services

Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company’s nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the DOD, and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.

Please visit us at http://www.perma-fix.com.

This press release contains “forward-looking statements” which are based largely on the Company’s expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company’s control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, but are not limited to: contracts that will contribute revenue in 2023; market outlook; contracts to be awarded in the coming quarters; and improved visibility for the balance of 2023. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; industry conditions; competitive pressures; our ability to apply and market our new technologies; the government or such other party to a contract granted to us fails to abide by or comply with the contract or to deliver waste as anticipated under the contract or terminates existing contracts; Congress fails to provides funding for the DOD’s and DOE’s remediation projects; inability to obtain new foreign and domestic remediation contracts; and the additional factors referred to under “Risk Factors” and “Special Note Regarding Forward-Looking Statements” of our 2022 Form 10-K and Form 10-Qs for quarters ended March 31, 2023 and June 30, 2023. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

FINANCIAL TABLES FOLLOW

Contacts:

David K. Waldman-US Investor Relations
Crescendo Communications, LLC
(212) 671-1021

Herbert Strauss-European Investor Relations
[email protected]
+43 316 296 316

PERMA-FIX ENVIRONMENTAL SERVICES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    Three Months Ended   Six Months Ended
    June 30,   June 30,
(Amounts in Thousands, Except for Per Share Amounts)   2023   2022   2023   2022
                 
Net revenues $ 25,032   $ 19,455   $ 45,139   $ 35,370  
Cost of goods sold   20,516     16,571     37,614     30,850  
Gross profit   4,516     2,884     7,525     4,520  
                 
Selling, general and administrative expenses   3,551     3,684     7,036     7,106  
Research and development   121     80     220     176  
Loss on disposal of property and equipment               1  
Income (loss) from operations   844     (880 )   269     (2,763 )
                 
Other income (expense):                
Interest income   172     29     298     40  
Interest expense   (47 )   (41 )   (100 )   (76 )
Interest expense-financing fees   (24 )   (15 )   (44 )   (28 )
Other   6     (3 )   7     (5 )
Income (loss) from continuing operations before taxes   951     (910 )   430     (2,832 )
Income tax expense (benefit)   432     347     228     (326 )
Income (loss) from continuing operations, net of taxes   519     (1,257 )   202     (2,506 )
                 
Loss from discontinued operations, net of taxes   (45 )   (188 )   (139 )   (282 )
Net income (loss) $ 474   $ (1,445 ) $ 63   $ (2,788 )
                 
                 
Net income (loss) per common share – basic:                
Continuing operations $ .04   $ (.10 ) $ .01   $ (.19 )
Discontinued operations   —      (.01 )   (.01 )   (.02 )
Net income (loss) per common share $ .04   $ (.11 ) $   $ (.21 )
                 
Net income (loss) per common share – diluted:                
Continuing operations $ .03   $ (.10 ) $ .01   $ (.19 )
Discontinued operations       (.01 )   (.01 )   (.02 )
Net income (loss) per common share $ .03   $ (.11 ) $   $ (.21 )
                 
Number of common shares used in computing                
net income (loss) per share:                
Basic   13,474     13,264     13,417     13,249  
Diluted   13,848     13,264     13,657     13,249  
                 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
 
    June 30,   December 31,
      2023       2023  
(Amounts in Thousands, Except for Share and Per Share Amounts)   (Unaudited)    
         
ASSETS        
Current assets:        
Cash   $ 4,750     $ 1,866  
Account receivable, net of allowance for credit losses of $13 and $57, respectively     11,930       9,364  
Unbilled receivables     7,121       6,062  
Other current assets     3,767       6,219  
Assets of discontinued operations included in current assets     17       15  
Total current assets     27,585       23,526  
         
Net property and equipment     18,832       18,957  
Property and equipment of discontinued operations     81       81  
         
Operating lease right-of-use assets     1,732       1,971  
         
Intangibles and other assets     26,350       26,363  
Total assets   $ 74,580     $ 70,898  
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities   $ 25,601     $ 22,346  
Current liabilities related to discontinued operations     280       362  
Total current liabilities     25,881       22,708  
         
Long-term liabilities     9,556       9,749  
Long-term liabilities related to discontinued operations     913       908  
Total liabilities     36,350       33,365  
Commitments and Contingencies        
Stockholders’ equity:        
Preferred Stock, $.001 par value; 2,000,000 shares authorized,        
no shares issued and outstanding    
Common Stock, $.001 par value; 30,000,000 shares authorized,        
13,562,743 and 13,332,398 shares issued, respectively;        
13,555,101 and 13,324,756 shares outstanding, respectively     14       13  
Additional paid-in capital     115,789       115,209  
Accumulated deficit     (77,373 )     (77,436 )
Accumulated other comprehensive loss     (112 )     (165 )
Less Common Stock held in treasury, at cost: 7,642 shares     (88 )     (88 )
Total stockholders’ equity     38,230       37,533  
         
Total liabilities and stockholders’ equity   $ 74,580     $ 70,898  
         



Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  • Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023
  • Opened 20 clinical sites and continues to enroll patients in a U.S. Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024
  • Completed enrollment of the dose-escalation portion of the Phase 1 combination arm of CTX-471 (CD137 agonistic antibody) and KEYTRUDA® (pembrolizumab)
  • Added to the Russell 2000® and Russell 3000® Indexes as part of the Russell indexes annual reconstitution
  • Ended the second quarter with $169 million in cash and marketable securities, providing cash runway for the company into 2026

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.

“Enrollment of our Phase 2 study of CTX-009 in patients with advanced CRC is on track and we expect to report initial data from this study in the second half of this year. Enrollment in our Phase 2 study in patients with BTC has been slower than anticipated, but we have taken steps to address this, including opening of a number of key clinical sites, strengthening our clinical operations team, and increasing our collaboration with patient advocacy groups,” said Thomas J. Schuetz, MD, PhD, Co-Founder and Chief Executive Officer.

“While we continue to advance CTX-009 and CTX-471 in the clinic, we are also gearing toward the filing of our third U.S. IND application, which will be for our next generation bispecific checkpoint axis blocker, CTX-8371. We believe that CTX-8371’s unique mechanism-of-action is the reason for its differentiated activity in pre-clinical studies, and we look forward to advancing it to a first-in-human clinical study,” said Vered Bisker-Leib, PhD, President and Chief Operating Officer.

Development Pipeline Update and Highlights:


CTX-009 (DLL4 and VEGF-A bispecific antibody)

  • Enrolling patients in the U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic colorectal cancer
    • The study design is an Adaptive Simon Two-Stage, with Stage 1 of the study enrolling 37 patients; if 3 or more responses are confirmed in Stage 1, the study will advance to Stage 2, and an additional 47 patients will be enrolled 
    • The study is enrolling patients with CRC who have received two or three prior systemic therapies irrespective of their KRAS mutation status  
    • Patients are being evaluated for safety and tolerability, as well as clinical response
    • Initial results from Stage 1 of this study are expected in the second half of 2023
  • Enrolling patients in the U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in BTC
    • This randomized Phase 2/3 study is designed to enroll 150 patients with BTC who have received one prior systemic therapy
    • The primary endpoint of the study is overall response rate (ORR), and secondary endpoints include progression free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and duration of response (DOR)
    • Enrollment for this study has been slower than anticipated; based on our current enrollment estimate, we expect top line data from this study in the second half of 2024  


CTX-471 (CD137 + PD-1)

  • Advancing enrollment of the Phase 1 combination arm of CTX-471 (CD137 agonistic antibody) and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with select solid tumors
  • The dose-escalation portion of the study (n=9) has been fully enrolled

Initial results from the combination arm are expected in the second half of 2023 


CTX-8371 (PD-1 x PD-L1)

  • CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique mechanism-of-action that involves cleavage of cell surface PD-1
  • Targeting IND submission in the third quarter of 2023 and initiating a Phase 1 clinical trial in the fourth quarter of 2023

Financial Results

Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, compared to $8.5 million or $0.08 per common share for the same period in 2022. Net loss for the six months ended June 30, 2022 was $19.1 million or $0.15 per common share, compared to $15.7 million or $0.16 per common share for the same period in 2022.

Cash Position

As of June 30, 2023, cash and marketable securities were $169 million as compared to $187 million as of December 31, 2022, providing the Company with an anticipated cash runway into 2026. During the first half of 2023, the Company used $22 million of cash to fund operations.

Research and development (R&D) Expenses

R&D expenses were $10.2 million for the quarter ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of approximately $4.4 million or 74%. The change for the quarter was primarily attributable to a net increase of $4.6 million in program costs, resulting primarily from $5.9 million additional spending related to CTX-009 clinical and manufacturing costs offset by a $1.3 million decrease in spending on other programs.

R&D expenses were $16.9 million for the six months ended June 30, 2023, as compared to $10.3 million for the same period in 2022, an increase of $6.6 million or 64%. The change for the year was primarily attributable to a net increase of $7.1 million in program costs, resulting primarily from $9.3 million additional spending related to CTX-009 clinical and manufacturing costs offset by a $2.2 million decrease in spending on other programs.

General and Administrative (G&A) Expenses

G&A expenses were $3.1 million for the quarter ended June 30, 2023 and 2022. G&A expenses were $6.2 million for the six months ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of $0.3 million or 5%.

Upcoming Investor Conferences

Compass management will participate in four upcoming investor conferences:

  • Wedbush Securities Healthcare Conference
    Date: August 8-9, 2023
    Location: New York, NY
  • Citi BioPharma Conference

    Date: September 6-7, 2023
    Location: Boston, MA
  • HC Wainwright Global Investment Conference

    Date: September 11-13, 2023
    Location: New York, NY
  • Cantor Healthcare Conference

    Date: September 26-28, 2023
    Location: New York, NY

Live webcasts presentations, when available, will be under “News & Events” in the Investors section of the Company’s website located at www.compasstherapeutics.com.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. 

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, their development, regulatory plans with respect thereto and therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the SEC available at www.sec.gov, including without limitation Compass’s latest Form 10-Q and subsequent filings with the SEC.

Investor Contact

[email protected]

Media Contact

Anna Gifford, Communications Manager
[email protected]
617-500-8099

   
Compass Therapeutics, Inc. and Subsidiaries  
Condensed Consolidated Balance Sheets  
(In thousands, except par value)  
           
    June 30, 2023   December 31, 2022  
    (unaudited)      
Assets          
Current assets:          
Cash and cash equivalents   $ 19,278   $ 34,946  
Marketable securities     149,474     151,663  
Prepaid expenses and other current assets     6,520     8,182  
Total current assets     175,272     194,791  
Property and equipment, net     1,204     1,567  
Operating lease, right-of-use (“ROU”) asset     2,385     2,967  
Other assets     320     320  
Total assets   $ 179,181   $ 199,645  
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable   $ 724   $ 3,382  
Accrued expenses     7,827     11,690  
Operating lease obligations, current portion     1,147     1,097  
Total current liabilities     9,698     16,169  
Operating lease obligations, long-term portion     1,197     1,838  
Total liabilities     10,895     18,007  
Total stockholders’ equity     168,286     181,638  
Total liabilities and stockholders’ equity   $ 179,181   $ 199,645  
           

Compass Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations (unaudited)
(In thousands, except per share data)
                 
    Three Months Ended June 30,   Six Months Ended June 30,
      2023       2022       2023       2022  
             
Operating expenses:                
Research and development   $ 10,223     $ 5,862     $ 16,862     $ 10,278  
General and administrative     3,114       3,125       6,183       5,891  
Total operating expenses     13,337       8,987       23,045       16,169  
Loss from operations     (13,337 )     (8,987 )     (23,045 )     (16,169 )
Other income     2,059       493       3,930       513  
Net loss   $ (11,278 )   $ (8,494 )   $ (19,115 )   $ (15,656 )
Net loss per share – basic and diluted   $ (0.09 )   $ (0.08 )   $ (0.15 )   $ (0.16 )
                 



Agilent Announces Thought Leader Award to Peter Neubauer

Agilent Announces Thought Leader Award to Peter Neubauer

Technical University of Berlin researcher recognized for his innovative work in bioprocess engineering

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.

Automation and high throughput are important for the real-time determination of critical quality attributes (CQAs), thus optimizing biotechnological applications. To this end, substantial resources are being directed toward developing process analytical technology (PAT) – a mechanism for designing, analyzing, and controlling pharmaceutical manufacturing processes by monitoring parameters that impact quality – to ultimately minimize public health risks.

Dr. Neubauer’s work orchestrates hardware, software, automation, mathematical models, and AI to discover optimal conditions for PAT end-to-end workflows. Integrating intelligent technologies and automation into PAT solutions is a key factor for moving the pharmaceutical industry toward optimized bioprocesses that improve safety and reduce hands-on intervention. The Agilent Thought Leader Award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies.

“We are truly grateful and excited that Agilent’s award will open up the opportunity to incorporate two-dimensional liquid chromatography and mass spectrometry into our upcoming bioprocess laboratory. The use of such leading-edge instrumentation is a fundamental element in our journey towards achieving a higher level in automated bioprocess development,” said Dr. Neubauer who established and heads the KIWI-biolab as an International Future Laboratory for AI for Intelligent Integrated Biolaboratories. “Given our recent progress in seamlessly orchestrating all devices required in the process, ranging from extensive analyte-specific sample preparation to the management of big data, we feel ready to conquer this next logical step of integration.”

“Agilent is pleased to grant this Thought Leader Award to Dr. Neubauer to support his scientific developments in the biopharma space,” said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions, and executive sponsor of the award. “His important work will help the pharmaceutical industry optimize their bioprocesses and accelerate improved healthcare worldwide.”

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

MEDIA CONTACT

Naomi Goumillout

Agilent Technologies

+1.978.314.1862

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Health Genetics Other Science Research Science Biotechnology

MEDIA:

Logo
Logo

Payoneer Adds Capabilities With Acquisition of Data Platform, Spott

Payoneer Adds Capabilities With Acquisition of Data Platform, Spott

Spott’s AI enhances Payoneer’s service offerings to expand services to customers across 190 countries

NEW YORK–(BUSINESS WIRE)–Payoneer (NASDAQ: PAYO), the financial technology company empowering the world’s small and medium-sized businesses (SMBs) to transact, do business, and grow globally, today announced the asset acquisition of Israel-based Spott, a real-time data platform that uses AI to accurately surface, assess, and quantify data for more informed and faster business decision-making. Spott’s technology will enable Payoneer to better understand and serve customers, which supports our mission to make it easier for SMBs to operate and grow their business around the world.

Harnessing Spott’s capabilities, Payoneer will analyze large sets of data to apply advanced AI models and make predictions and decisions about its service offerings for a global SMB customer base. The first application of the technology will be on the Payoneer working capital products to enhance underwriting capabilities.

“Today’s announcement is part of Payoneer’s commitment to investing in AI and data to provide unique and seamless experiences for our customers,” saidAssaf Ronen, Chief Platform Officer at Payoneer. “We look forward to seeing the impact that these capabilities will have on Payoneer customers. Spott has built a strong solution, and as part of Payoneer, this innovative technology will be available to SMBs in nearly 200 countries and territories.”

“This is another exciting step on the journey for us. We believe in the impact our technology can have on Payoneer’s global customers and today’s announcement means the solution can help more businesses around the world,” said Amit Batzir, Co-founder and CEO at Spott. “Payoneer was a natural fit for the vision we have for our technology, and we look forward to working with the team and building for the future.”

As part of the transaction, Spott’s co-founders, CEO Amit Batzir and CTO Roma Bronstein will join Payoneer’s Technology team, also based in Israel.

About Payoneer

Payoneer is the financial technology company empowering the world’s small and medium-sized businesses to transact, do business and grow globally. Payoneer was founded in 2005 with the belief that talent is equally distributed, but opportunity is not. It is our mission to enable anyone anywhere to participate and succeed in the global digital economy. Since our founding, we have built a global financial platform that has already made it easier for millions of SMBs, particularly in emerging markets, to pay and get paid, manage their funds, and grow their business.

Forward-Looking Statements

This press release includes, and oral statements made from time to time by representatives of Payoneer, may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Payoneer’s future financial or operating performance. For example, projections of future revenue, transaction cost and adjusted EBITDA are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “plan,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Payoneer and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in applicable laws or regulations; (2) the possibility that Payoneer may be adversely affected by geopolitical and other economic, business and/or competitive factors; (3) Payoneer’s estimates of its financial performance; (4) the outcome of any known and/or unknown legal or regulatory proceedings; and (5) other risks and uncertainties set forth in Payoneer’s Annual Report on Form 10-K for the period ended December 31, 2022 and future reports that Payoneer may file with the SEC from time to time. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Payoneer does not undertake any duty to update these forward-looking statements.

Investors 

[email protected] 

Media 

[email protected] 

KEYWORDS: New York United States North America Israel Middle East

INDUSTRY KEYWORDS: Professional Services Data Management Business Small Business Technology Fintech Artificial Intelligence

MEDIA:

Logo
Logo

Magnite Announces Integration into FreeWheel’s TV Platform, Allowing Publishers a More Aggregated View of Demand Across the Premium TV Ecosystem

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — Today, Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company, announced a technical integration with FreeWheel, a global technology platform for the television advertising industry, to enhance the ability of FreeWheel technology users to see multiple sources of demand in one platform, across both programmatic and direct transactions.

“We are committed to enhancing interoperability across the premium TV ecosystem and welcome Magnite as one of our new integration partners,” said Soo Jin Oh, Chief Strategy Officer at FreeWheel. “By better integrating Magnite’s programmatic technology, we continue to execute on our goal of maximizing competition and demand for our clients’ inventory via unified ad decisioning within FreeWheel’s TV Platform. Ultimately, this will not only benefit inventory owners and buyers, but also will improve the viewing experience for consumers.”

FreeWheel will integrate programmatic requests from Magnite into its TV platform to provide FreeWheel’s publisher clients with enhanced unified decisioning capabilities, now inclusive of Magnite’s programmatic technology. This means that mutual publisher clients will have better insight into ad creative, frequency capping and holistic management across systems and sales execution types. This will enable those inventory owners on the FreeWheel platform to better maximize yield, while also improving the overall experience for advertisers, including better alignment to media goals and adherence to business rules.

“The growth of programmatic advertising in streaming video has been transformative, enabling advertisers to reach their audiences with greater accuracy and efficiency than ever before,” said Sean Buckley, Chief Revenue Officer at Magnite. “By enabling media owners to manage their revenue streams holistically across programmatic and traditional direct sales, this integration with FreeWheel will enable programmatic to remain an integrated part of publishers’ sales strategies and will help accelerate growth even further.”

“Efforts to drive interoperability and unify decisioning across demand sources are key to helping media companies manage inventory and optimize advertising solutions in an increasingly complex TV ecosystem,” said Jill Steinhauser, Senior Vice President, Ad Sales Planning and Operations at Warner Bros. Discovery. “FreeWheel and Magnite are paving the way for greater interoperability and helping to solve for one of the industry’s most pressing challenges.”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

About FreeWheel

FreeWheel empowers all segments of The New TV Ecosystem. We are structured to provide the full breadth of solutions the advertising industry needs to achieve their goals. We provide the technology, data enablement and convergent marketplaces required to ensure buyers and sellers can transact across all screens, across all data types, and all sales channels, in order to ensure the ultimate goal – results for marketers. With offices in New York, San Francisco, Chicago, London, Paris, Beijing, and across the globe, FreeWheel, A Comcast Company, stands to advocate for the entire industry through the FreeWheel Council for Premium Video. For more information, please visit freewheel.com, and follow us on Twitter and LinkedIn.

Media Contacts:

Magnite
Charlstie Veith
[email protected]

FreeWheel
Elaine Wong
[email protected]

Investor Relations Contact:

Nick Kormeluk
[email protected]